HK1208618A1 - Pulmonary delivery of mrna to non-lung target cells mrna - Google Patents

Pulmonary delivery of mrna to non-lung target cells mrna

Info

Publication number
HK1208618A1
HK1208618A1 HK15109129.8A HK15109129A HK1208618A1 HK 1208618 A1 HK1208618 A1 HK 1208618A1 HK 15109129 A HK15109129 A HK 15109129A HK 1208618 A1 HK1208618 A1 HK 1208618A1
Authority
HK
Hong Kong
Prior art keywords
mrna
target cells
pulmonary delivery
lung target
lung
Prior art date
Application number
HK15109129.8A
Other languages
English (en)
Chinese (zh)
Inventor
‧哈特萊因
‧吉爾德
‧德羅莎
‧魯道夫
‧普蘭克
Original Assignee
Shire Human Genetic Therapies
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies, Ethris Gmbh filed Critical Shire Human Genetic Therapies
Publication of HK1208618A1 publication Critical patent/HK1208618A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15109129.8A 2012-06-08 2015-09-17 Pulmonary delivery of mrna to non-lung target cells mrna HK1208618A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657452P 2012-06-08 2012-06-08
PCT/US2013/044771 WO2013185069A1 (en) 2012-06-08 2013-06-07 Pulmonary delivery of mrna to non-lung target cells

Publications (1)

Publication Number Publication Date
HK1208618A1 true HK1208618A1 (en) 2016-03-11

Family

ID=49712697

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108982.6A HK1208352A1 (en) 2012-06-08 2015-09-14 Pulmonary delivery of mrna to non-lung target cells mrna
HK15109129.8A HK1208618A1 (en) 2012-06-08 2015-09-17 Pulmonary delivery of mrna to non-lung target cells mrna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15108982.6A HK1208352A1 (en) 2012-06-08 2015-09-14 Pulmonary delivery of mrna to non-lung target cells mrna

Country Status (12)

Country Link
US (3) US10245229B2 (xx)
EP (2) EP2858679B2 (xx)
JP (3) JP6561378B2 (xx)
CN (1) CN104519915A (xx)
AU (2) AU2013271392B2 (xx)
BR (1) BR112014030677A2 (xx)
CA (1) CA2876155C (xx)
EA (1) EA201492055A1 (xx)
ES (1) ES2864878T3 (xx)
HK (2) HK1208352A1 (xx)
MX (1) MX2014015041A (xx)
WO (1) WO2013185069A1 (xx)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP2718269B1 (en) 2011-06-08 2018-01-31 Translate Bio, Inc. Cleavable lipids
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
SG10201604896TA (en) 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
DK2830595T3 (da) * 2012-03-29 2019-12-02 Translate Bio Inc Ioniserbare kationiske lipider
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP3628335B1 (en) * 2012-12-07 2023-11-08 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery in the lungs
NZ751462A (en) 2013-03-14 2021-07-30 Shire Human Genetic Therapies Cftr mrna compositions and related methods and uses
BR112015022660A2 (pt) 2013-03-14 2017-10-31 Shire Human Genetic Therapies métodos para a purificação de rna mensageiro
CN105209490A (zh) 2013-03-14 2015-12-30 夏尔人类遗传性治疗公司 用于递送mrna编码的抗体的方法和组合物
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
EP4332576A3 (en) 2013-03-15 2024-04-24 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3019619B1 (en) 2013-07-11 2021-08-25 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CN110974981A (zh) * 2013-07-23 2020-04-10 野草莓树生物制药公司 用于递送信使rna的组合物和方法
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP4276176A3 (en) * 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
HUE057800T2 (hu) 2014-04-23 2022-06-28 Modernatx Inc Nukleinsav vakcinák
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
MA56412A (fr) 2014-12-05 2022-05-04 Translate Bio Inc Thérapie par l'arn messager pour le traitement des maladies articulaires
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
WO2016184576A2 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
SG10201910431RA (en) 2015-05-20 2020-01-30 Curevac Ag Dry powder composition comprising long-chain rna
CN113897350A (zh) 2015-05-29 2022-01-07 库瑞瓦格房地产有限公司 包括至少一个切向流过滤步骤的产生和纯化rna的方法
KR102627853B1 (ko) 2015-06-30 2024-01-22 에트리스 게엠베하 Atp―결합 카세트 패밀리 코딩 폴리리보뉴클레오티드 및 그의 제제
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342376A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
SG11201803365RA (en) * 2015-10-22 2018-05-30 Modernatx Inc Herpes simplex virus vaccine
TW201729836A (zh) * 2015-10-22 2017-09-01 現代公司 呼吸道融合病毒疫苗
EP3364983A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST RESPIRATORY VIRUS
CA3003103A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EA201891001A1 (ru) * 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
WO2017100562A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc, Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017112865A1 (en) 2015-12-22 2017-06-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017139588A1 (en) * 2016-02-12 2017-08-17 Indiana University Research & Technology Corporation Lysosomal acid lipase and ppar gamma ligands as an immune therapies for cancer treatment
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
MA45053A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique
EP3458590B9 (en) 2016-05-18 2021-08-18 ModernaTX, Inc. Polynucleotides encoding -galactosidase a for the treatment of fabry disease
KR102533456B1 (ko) * 2016-05-18 2023-05-17 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
EP4186518A1 (en) 2016-05-18 2023-05-31 ModernaTX, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
EP3469074B1 (en) * 2016-06-13 2020-12-09 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
EP3478838A1 (en) 2016-06-30 2019-05-08 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11104887B2 (en) 2017-01-03 2021-08-31 Ethris Gmbh Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US10975369B2 (en) 2017-02-27 2021-04-13 Translate Bio, Inc. Methods for purification of messenger RNA
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US10808241B2 (en) 2017-02-27 2020-10-20 Translate Bio, Inc. Methods for purification of messenger RNA
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
KR20190132405A (ko) 2017-03-15 2019-11-27 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 화합물 및 조성물
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
KR101960954B1 (ko) * 2017-06-21 2019-03-22 한국생명공학연구원 혈액 바이오마커를 이용한 근력 약화 관련 질환의 진단 방법 및 키트
US20200165593A1 (en) 2017-07-21 2020-05-28 Modernatx, Inc. Modified mRNA Encoding a Propionyl-CoA Carboxylase and Uses Thereof
US20200179494A1 (en) 2017-07-24 2020-06-11 Modernatx, Inc. Modified mRNA Encoding a Glucose 6 Phosphatase and Uses Thereof
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
WO2019104152A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
CA3084061A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019131770A1 (ja) * 2017-12-27 2019-07-04 武田薬品工業株式会社 核酸含有脂質ナノ粒子及びその用途
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2019173632A1 (en) * 2018-03-07 2019-09-12 Icahn School Of Medicine At Mount Sinai Modrna encoding sphingolipid-metabolizing proteins
AU2019266548A1 (en) 2018-05-10 2021-01-07 Complement Therapeutics Limited Methods for assessing macular degeneration
US20210220449A1 (en) * 2018-05-15 2021-07-22 Translate Bio, Inc. Subcutaneous Delivery of Messenger RNA
EP3813871A4 (en) 2018-06-29 2022-10-12 Icahn School of Medicine at Mount Sinai SPHINGOLIPID METABOLIZING PROTEINS ENCODING FOR ANC80
CA3107055A1 (en) * 2018-07-23 2020-01-30 Translate Bio, Inc. Dry powder formulations for messenger rna
EA202190368A1 (ru) * 2018-08-24 2021-06-10 ФЛЭГШИП ПАЙОНИРИНГ ИННОВЕЙШНЗ VI, ЭлЭлСи Модифицированные пакеты-мессенджеры растений и варианты их применения
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
CA3111476A1 (en) 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
WO2020070040A1 (en) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Rna particles comprising polysarcosine
HUE066181T2 (hu) 2018-10-09 2024-07-28 Univ British Columbia Szerves oldószerektõl és detergensektõl mentes transzfekció-kompetens vezikulumokat tartalmazó készítmények és rendszerek, és az azokkal kapcsolatos eljárások
EP3877538A1 (en) 2018-11-08 2021-09-15 Translate Bio, Inc. Methods and compositions for messenger rna purification
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20220211807A1 (en) * 2019-02-14 2022-07-07 Ethris Gmbh Treatment of ciliopathies
CN114615985A (zh) * 2019-09-11 2022-06-10 西奈山伊坎医学院 包含修饰mRNA的分子的组合物及其使用方法
KR20220101077A (ko) 2019-09-19 2022-07-19 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 분지형 꼬리 지질 화합물 및 조성물
US20210106527A1 (en) * 2019-10-09 2021-04-15 Translate Bio, Inc. Compositions, methods and uses of messenger rna
EP4096710A1 (en) 2020-01-28 2022-12-07 ModernaTX, Inc. Coronavirus rna vaccines
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
CA3170150A1 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
CN111929441B (zh) * 2020-08-17 2022-10-21 南通大学附属医院 肺癌诊断及其预后评估中使用的生物标记物及试剂盒
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022058447A1 (en) 2020-09-16 2022-03-24 The University Of Manchester Complementome assay
EP4217371A1 (en) 2020-09-25 2023-08-02 ModernaTX, Inc. Multi-proline-substituted coronavirus spike protein vaccines
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
WO2022125713A1 (en) * 2020-12-09 2022-06-16 Aravasc Inc. Polymeric micelle complexes of mrna or zwitterionic agents, and formulations and uses thereof
CN112553328B (zh) * 2020-12-30 2022-06-17 浙江大学 检测基因表达水平的产品及其在制备重度抑郁症诊断工具中的应用
US20230000970A1 (en) 2021-01-11 2023-01-05 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022155530A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
WO2022155524A1 (en) 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022237382A1 (en) 2021-03-15 2023-09-28 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
AU2022246065A1 (en) * 2021-03-22 2023-10-12 Recode Therapeutics, Inc. Compositions and methods for targeted delivery to cells
WO2022221335A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory virus combination vaccines
JP2024513999A (ja) 2021-04-14 2024-03-27 モデルナティエックス インコーポレイテッド インフルエンザ－コロナウイルス組み合わせワクチン
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
WO2022264109A1 (en) 2021-06-18 2022-12-22 Sanofi Multivalent influenza vaccines
CA3227081A1 (en) 2021-08-24 2023-03-02 Irena RABE In vitro transcription technologies
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023069498A1 (en) 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
CN118488834A (zh) 2021-11-23 2024-08-13 赛欧生物医药股份有限公司 细菌源性脂质组合物和其用途
AR127808A1 (es) 2021-11-30 2024-02-28 Sanofi Pasteur Inc Vacunas contra el metapneumovirus humano
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
IL292957A (en) 2022-05-11 2023-12-01 Yeda res & development co ltd Treatment of heart disease
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
GB202214445D0 (en) 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
WO2024094876A1 (en) 2022-11-04 2024-05-10 Sanofi Methods for messenger rna tailing
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024126847A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna recombinant capping enzymes
WO2024126809A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna encoding influenza virus-like particle
WO2024133884A2 (en) 2022-12-23 2024-06-27 Sanofi Optimized tailing of messenger rna
WO2024146953A1 (en) 2023-01-05 2024-07-11 Complement Therapeutics Limited Agents and methods for treating complement diseases
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
CN117919200A (zh) * 2024-01-19 2024-04-26 晟迪生物医药(苏州)有限公司 含有可电离脂质的肺部递送系统、其制备方法和应用

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
EP0465529B1 (en) 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
JPH06510036A (ja) * 1991-08-16 1994-11-10 バイカル・インコーポレイテッド 嚢胞性線維症の治療のための組成物および方法
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP1489184A1 (en) 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
ES2305157T3 (es) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
IL145592A0 (en) 1999-04-02 2002-06-30 Res Dev Foundation Polyethyleneimine: dna formulations for aerosol delivery
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
CA2512808A1 (en) * 2003-01-18 2004-08-12 Marc Elliot Rothenberg Regulation of allergen induced gene
US20040224912A1 (en) * 2003-05-07 2004-11-11 Isis Pharmaceuticals Inc. Modulation of PAI-1 mRNA-binding protein expression
AU2004272646B2 (en) 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
GB0418172D0 (en) 2004-08-13 2004-09-15 Ic Vec Ltd Vector
JP2008509205A (ja) * 2004-08-13 2008-03-27 アイシー・ベック・リミテッド ポリマー修飾ｓｉＲＮＡリポソームを含むベクター
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
JP2008528033A (ja) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス， インコーポレイテッド ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
EP2578685B1 (en) 2005-08-23 2019-04-17 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
WO2009088891A1 (en) 2008-01-02 2009-07-16 Alnylam Pharmaceuticals, Inc. Screening method for selected amino lipid-containing compositions
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
DE102008001783A1 (de) 2008-05-15 2009-11-19 Deere & Company, Moline Messanordnung zur Bestimmung der Inhaltsstoffe einer aus einem Erntegutstrom entnommenen Probe
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
KR101734955B1 (ko) * 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 아미노알콜 리피도이드 및 그의 용도
CN105152939A (zh) 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
WO2010056403A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Branched cationic lipids for nucleic acids delivery system
EP2405921A4 (en) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
JPWO2010110314A1 (ja) 2009-03-27 2012-10-04 協和発酵キリン株式会社 核酸を含有する肺高血圧症治療剤
WO2010124004A2 (en) 2009-04-22 2010-10-28 Emory University Nanocarrier therapy for treating invasive tumors
US8883202B2 (en) 2009-05-05 2014-11-11 Tekmira Pharmaceuticals Corporation Lipid compositions
SG10201912450XA (en) 2009-06-10 2020-03-30 Arbutus Biopharma Corp Improved lipid formulation
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US20120195936A1 (en) * 2009-07-31 2012-08-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
JP2013512690A (ja) * 2009-12-07 2013-04-18 ザ トラスティース オブ ザ ユニバーシティ オブ ペンシルベニア 細胞を再プログラム化するための精製された修飾ｒｎａを含むｒｎａ調製物
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
JP5893611B2 (ja) 2010-06-03 2016-03-23 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性剤の送達のための生分解性脂質
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN103687957A (zh) 2011-05-17 2014-03-26 现代治疗公司 工程化核酸及其用于非人类脊椎动物的方法
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
EP2718269B1 (en) 2011-06-08 2018-01-31 Translate Bio, Inc. Cleavable lipids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2755986A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MODIFIED NUCLEIC ACIDS AND METHODS OF USE
RU2014117690A (ru) 2011-10-05 2015-11-10 Протива Байотерапьютикс Инк. Композиции и способы для сайленсинга альдегид-дегидрогеназы
WO2013090186A1 (en) 2011-12-14 2013-06-20 modeRNA Therapeutics Modified nucleic acids, and acute care uses thereof
EP2791364A4 (en) 2011-12-14 2015-11-11 Moderna Therapeutics Inc METHODS OF RESPONSE TO A BIOLOGICAL THREAT
SG10201604896TA (en) 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CN104968354A (zh) 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
ES2702874T3 (es) 2012-02-24 2019-03-06 Arbutus Biopharma Corp Lípidos catiónicos de trialquilo y métodos para su uso
DK2830595T3 (da) * 2012-03-29 2019-12-02 Translate Bio Inc Ioniserbare kationiske lipider
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140275229A1 (en) 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US20150050354A1 (en) 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP3628335B1 (en) 2012-12-07 2023-11-08 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery in the lungs
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
EP2968397A4 (en) 2013-03-12 2016-12-28 Moderna Therapeutics Inc DIAGNOSIS AND TREATMENT OF FIBROSIS
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP3019619B1 (en) 2013-07-11 2021-08-25 ModernaTX, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CN110974981A (zh) 2013-07-23 2020-04-10 野草莓树生物制药公司 用于递送信使rna的组合物和方法
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
SG10201903381TA (en) 2013-12-30 2019-05-30 Curevac Ag Artificial nucleic acid molecules
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
HUE057800T2 (hu) 2014-04-23 2022-06-28 Modernatx Inc Nukleinsav vakcinák
EP3201338B1 (en) 2014-10-02 2021-11-03 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
WO2016071857A1 (en) 2014-11-07 2016-05-12 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus expression
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
US20170362627A1 (en) 2014-11-10 2017-12-21 Modernatx, Inc. Multiparametric nucleic acid optimization
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
CA2979998A1 (en) 2015-03-20 2016-09-29 Protiva Biotherapeutics, Inc. Compositions and methods for treating hypertriglyceridemia
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
WO2016183366A2 (en) 2015-05-12 2016-11-17 Protiva Biotherapeutics, Inc. Compositions and methods for silencing expression of hepatitis d virus rna
US10626393B2 (en) 2015-06-04 2020-04-21 Arbutus Biopharma Corporation Delivering CRISPR therapeutics with lipid nanoparticles
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression

Also Published As

Publication number Publication date
EP2858679B2 (en) 2024-06-05
CN104519915A (zh) 2015-04-15
US10245229B2 (en) 2019-04-02
AU2018203310B2 (en) 2020-05-14
JP6913699B2 (ja) 2021-08-04
JP2019065052A (ja) 2019-04-25
CA2876155C (en) 2022-12-13
MX2014015041A (es) 2015-06-17
JP2017206567A (ja) 2017-11-24
JP2015520195A (ja) 2015-07-16
AU2018203310A1 (en) 2018-05-31
EP2858679A4 (en) 2016-01-13
US11090264B2 (en) 2021-08-17
US20190216730A1 (en) 2019-07-18
EP2858679A1 (en) 2015-04-15
ES2864878T3 (es) 2021-10-14
WO2013185069A1 (en) 2013-12-12
US20150157565A1 (en) 2015-06-11
US20220226236A1 (en) 2022-07-21
BR112014030677A2 (pt) 2022-07-19
EP3884949A1 (en) 2021-09-29
EA201492055A1 (ru) 2015-11-30
EP2858679B1 (en) 2021-02-24
JP6561378B2 (ja) 2019-08-21
AU2013271392B2 (en) 2018-02-15
HK1208352A1 (en) 2016-03-04
CA2876155A1 (en) 2013-12-12
AU2013271392A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1208618A1 (en) Pulmonary delivery of mrna to non-lung target cells mrna
HK1209340A1 (en) Pulmonary delivery of messenger rna rna
HK1201658A1 (en) Secure distribution of content
ZA201502433B (en) Methods of host cell modification
EP2798594A4 (en) VIRTUAL POINT OF SALE
SI3243526T1 (sl) Dostava RNA za sprožitev večih imunskih poti
PL2791160T3 (pl) Kompozycje zmodyfikowanego mrna
EP2715273A4 (en) DART SET WITH MULTIPLE TARGETS
IL236525A0 (en) Antibodies against conserved targets
EP2771455A4 (en) CELL LINE FOR GENERATING AN ADENO-ASSOCIATED VIRUS
EP2761911A4 (en) PERSONAL SALES POINT
EP2737914A4 (en) LIQUID COLLECTOR
GB201111460D0 (en) Point of sale system
GB201204905D0 (en) Transport of cells
EP3030244A4 (en) Polyconjugates for delivery of rnai triggers to tumor cells in vivo
HK1208040A1 (en) Cell penetrating peptides to target eif4e eif4e
EP2696678A4 (en) MEDIUM FOR IMPROVED ADMINISTRATION OF NUCLEIC ACIDS IN EUKARYOTIC CELLS
GB201311220D0 (en) Improved structure of shoe
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
IL231663A0 (en) Vaccines directed at presenting dendritic cells
EP2830131A4 (en) CELL STRUCTURE OF FUEL CELL
EP2661489A4 (en) METHOD FOR INCREASING THE DELIVERY OF GEN-TRANSDUCED CELLS
GB201312378D0 (en) Structure of shoe
EP2716652A4 (en) FATTY ANTI-ACID SYNTHASE POLYPEPTIDE AND USE THEREOF
ZA201401599B (en) Preparation of methacrylic acid